Back to Search
Start Over
Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial.
- Source :
-
Leukemia & lymphoma [Leuk Lymphoma] 2014 Mar; Vol. 55 (3), pp. 695-7. Date of Electronic Publication: 2013 Jul 29. - Publication Year :
- 2014
- Subjects :
- Antibodies, Monoclonal, Humanized administration & dosage
Antibodies, Monoclonal, Humanized adverse effects
Antineoplastic Agents administration & dosage
Antineoplastic Agents adverse effects
Cetuximab
Humans
Multiple Myeloma mortality
Neoplasm Recurrence, Local
Treatment Outcome
Antibodies, Monoclonal, Humanized therapeutic use
Antineoplastic Agents therapeutic use
ErbB Receptors antagonists & inhibitors
Multiple Myeloma drug therapy
Multiple Myeloma pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1029-2403
- Volume :
- 55
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Leukemia & lymphoma
- Publication Type :
- Report
- Accession number :
- 23713484
- Full Text :
- https://doi.org/10.3109/10428194.2013.809074